Browse studies

Find your next paid study

3,220 recruiting studies matching your filters

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Pancreatic Cancer

The purpose of this research study is to test a new process for diagnosing pancreatic cancer by examining changes to your DNA that can be detected from a blood…

Pancreatic Cancer, Advanced or Metastatic

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Maryland, BaltimoreNCT07528430

Phase 1

Combination of Autophagy Selective Therapeutics (COAST) in Advanced Solid Tumors or Relapsed Prostate Cancer, A Phase I/II Trial

The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers…

Prostate Cancer RecurrentSolid Tumor, Adult

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Medical University of South CarolinaNCT05036226

The LINFU® (A Noninvasive Method for Increasing Exfoliation of Pancreatic Ductal Cells Into Pancreatic Fluid) U.S. Registry for the Detection of Low and High- Grade Atypia and Early, Asymptomatic Pancreatic Ductal Adenocarcinoma (PDAC)

Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic can…

Pancreatic AdenocarcinomaPancreatic Intraepithelial Neoplasia

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Adenocyte, LLCNCT06157671

Collection of ECG Recordings Using the HeartBeam 3-Lead ECG Recorder

The HeartBeam ECG Registry will collect ECG recordings acquired with the HeartBeam System with relevant clinical information in clinical settings.

Atrial FibrillationAtrial FlutterBradycardia+2 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

HeartBeam, Inc.NCT07501299

Phase 1

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients wi…

Advanced EGFR Positive Solid Tumor

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Changchun Intellicrown Pharmaceutical Co. LTDNCT04412616

Phase 1

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharma…

Gastric or Gastroesophageal Junction AdenocarcinomaPancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)+1 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Phanes Therapeutics

Phase 1

Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedure…

Recurrent World Health Organization (WHO) Grade II GliomaRecurrent WHO Grade III GliomaWHO Grade II Glioma+1 more

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Susan ChangNCT04540107

Phase 1

A Phase I/IIa Study to Evaluate the Efficacy of DB107-RRV (Formerly Toca511), Administered to Subjects at Time of Resection and Intravenously Thereafter, in Combination With DB107-FC (Formerly Toca FC) and Radiation Therapy or DB107-FC, Temozolomide (TMZ) and Radiation Therapy in Patients With Newly Diagnosed High Grade Glioma

This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newl…

High Grade GliomaMGMT-Unmethylated GlioblastomaMGMT-Methylated Glioblastoma

Estimated

~$150 – $2,700

Actual pay is set by the research site.

University of California, San FranciscoNCT06504381

Phase 1

A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics, and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy (ARTEMIDE-subQ)

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to eval…

Advanced Solid Tumors

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AstraZenecaNCT07161414

Role of Human Microbiome in Head and Neck Cancer

This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.

Head and Neck CancerLip CancerOral Cancer+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Colorado, DenverNCT05837221

Dose-response Analysis of Nivolumab/Relatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor a…

Locally Advanced Melanoma

Estimated

~$10 – $1,125

Actual pay is set by the research site.

John KirkwoodNCT07223411

Observational

PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for…

PDAC - Pancreatic Ductal Adenocarcinoma

Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts General HospitalNCT07047807